Carlo Incerti was appointed to the Numab Board of Directors in June 2021. He currently holds the position of Operating Partner at Forbion. A medical doctor by training, Carlo Incerti brings over three decades of experience in the biopharmaceutical industry. He most recently held the position of Senior Vice President, Chief Medical Officer and Head of Global Medical Affairs at Sanofi Genzyme.
Before his time at Sanofi and Genzyme, Carlo was a founding shareholder, Board member, and Chief Executive officer at Biofil S.r.l., a start-up active in the development, manufacturing, and commercialization of systems for leukocyte depletion of blood and derivatives, which was acquired by Fresenius Kabi of Germany in 1993.
Prior to joining the industry, Carlo was an Associate Professor of Endocrinology at the University of Modena, with a main research focus on thyroid diseases and sex hormones.
Dr. Incerti currently also serves on the board of Azafaros B.V. (Chairman), EryDel S.p.A (Chairman), Inversago Pharma (Chairman), VectorY (Chairman), and is a Founding Member and on the Consortium Assembly of IRDiRC, the International Rare Diseases Research Consortium.